Keith F. Martin
Vorstandsvorsitzender bei Apitope Technology (Bristol) Ltd.
Profil
Keith F.
Martin is currently the Chief Executive Officer at Apitope Technology (Bristol) Ltd.
He previously worked as the Chief Executive Officer & Director at Apitope International NV from 2012 to 2018.
Prior to that, he was the Global Director-Life Sciences at BTG, Inc. and a Director at Life Sciences, Inc. He also worked as a Principal at BASF Pharma Ltd.
Aktive Positionen von Keith F. Martin
Unternehmen | Position | Beginn |
---|---|---|
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Vorstandsvorsitzender | 01.06.2010 |
Ehemalige bekannte Positionen von Keith F. Martin
Unternehmen | Position | Ende |
---|---|---|
BTG, Inc.
BTG, Inc. Information Technology ServicesTechnology Services BTG, Inc. provides information systems and technical services to government and commercial enterprises. The company was founded in 1982 and is headquartered in Fairfax, VA. | Corporate Officer/Principal | - |
Life Sciences, Inc.
Life Sciences, Inc. Medical SpecialtiesHealth Technology Life Sciences, Inc. is a private company that is committed to saving lives and futures by providing superior products and services for scientific research. The company is based in St. Petersburg, FL. The company's offerings include AMV-RT, T7 RNA Polymerase, RNase H, NASBA, Lyophilized Products, and Services. The company was founded by Roderick N. Carter. | Direktor/Vorstandsmitglied | - |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Corporate Officer/Principal | - |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Vorstandsvorsitzender | 24.10.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
BTG, Inc.
BTG, Inc. Information Technology ServicesTechnology Services BTG, Inc. provides information systems and technical services to government and commercial enterprises. The company was founded in 1982 and is headquartered in Fairfax, VA. | Technology Services |
Life Sciences, Inc.
Life Sciences, Inc. Medical SpecialtiesHealth Technology Life Sciences, Inc. is a private company that is committed to saving lives and futures by providing superior products and services for scientific research. The company is based in St. Petersburg, FL. The company's offerings include AMV-RT, T7 RNA Polymerase, RNase H, NASBA, Lyophilized Products, and Services. The company was founded by Roderick N. Carter. | Health Technology |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |